Select Page
Event info
Date:12 Jun
Time:12:00 - 17:00
Venue:Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark - Meeting room: Auditorium
Contact person
Louise Fur Høier

Louise Fur Høier

Event Manager & PA to CEO

lfh@mva.org

+45 2073 5408

Medicon Valley Alliance Boost Seminar – Maximising Value: Navigating Market Access, Launch, and Commercialisation Challenges

Join us for this event to explore the lessons learned by senior industry experts who have successfully developed, launched, and commercialised global assets. Through a combination of real-life case-studies, panel discussions, and presentations we will explore how and when you should build your market access and commercialisation strategies, no matter your corporate strategy. This seminar will focus on key learnings and take-aways which will apply across biopharmaceuticals, medical device, digital medicine, and diagnostics therefore anyone who is currently in the life sciences business should benefit attending and take away critical learnings.

Key components:

  • Understanding commercialisation challenges and opportunities across biopharmaceuticals, medical devices, and diagnostics
  • Communicating value to potential partners and investors
  • Market Access Case Studies: Forewarned is forearmed, starting early to ensure success.
  • A walk through the key considerations gleaned from commercialising 20+ product launches.

About EVERSANA
EVERSANA® is the leading independent provider of global services to the life sciences industry. Our integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. We serve more than 670 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.

Date: Monday 12th June, 2023
Time: 12.00 – 17.00 CEST
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium

SIGN UP

Program

12:00 Registration & light lunch
12:30 Welcome and introduction to Medicon Valley Alliance
Anette Steenberg, CEO, Medicon Valley Alliance
12:45 The secret of Successful Drug Launches
Jason O’Neill, Former Dendreon CEO, Executive in Residence, EVERSANA
13:30 CEO PANEL DISCUSSION: Commercialisation considerations to maximise opportunities and minimise risk
Jason O’Neill, Former Dendreon CEO, Executive in Residence, EVERSANA
Jan Van Acker, SVP, Global Human Health, MSD
Kåre Engkilde, Executive Leader, Smile Incubator
Chaired by Ashley Cox, Senior Principal, Head of Europe, EMC
14:15  Coffee & Networking
14:45 Market Access Case Studies – Maximizing Your Launch Trajectory
David Byram, Senior Principal, EMC
15:00 CEO PANEL DISCUSSION: Market Access planning to ensure success
Jason O’Neill, Former Dendreon CEO, Executive in Residence, EVERSANA
Jan Van Acker, SVP, Global Human Health, MSD
Kåre Engkilde, Executive Leader, Smile Incubator
Chaired by David Byram, Senior Principal, EMC
15:45 Q&A
16:15 Closing Presentation
Jim Lang, CEO, EVERSANA
16:30 Networking, drinks, and light refreshments

 

Speakers​​

Jason O’Neill, Former Dendreon CEO, Executive in Residence, EVERSANA
Jason O’Neill is a global pharmaceutical executive with a passion for developing and launching new products. He served as a Vice President of U.S. Marketing, Asia Pacific Marketing and Global Marketing and later served as a country manager for Sanofi, a Franchise Head for Genentech and a General Manager for Mallinckrodt. He also served as a Global Therapeutic Area Head for Immunology and Ophthalmology for Roche where he oversaw the Phase III development and global commercialization of eight biologics in categories ranging from rheumatoid arthritis to ulcerative colitis. Most recently he served as the CEO of Dendreon Pharmaceuticals where he led the turnaround of Dendreon’s core prostate cancer business while launching a new contract manufacturing services division to support emerging cellular immunotherapies like CAR-T’s. He has played a primary role in eight new product launches and three new business unit launches and this experience has helped him pressure test the concepts that he will present. Jason is a graduate of Yale University and the J.L. Kellogg Graduate School of Management.

Jan Van Acker, SVP, Global Human Health, MSD
Jan Van Acker is SVP at MSD and co-leader of a corporate team responsible for designing and rolling out a new enterprise go-to-market model across R&D, manufacturing and commercial. He is also a board member of MSD’s Global Health Innovation Fund, a US $500M evergreen fund that invests in digital healthcare solutions. Jan is passionate about making a difference for patients by bringing his skills and experience to bear on complex and important healthcare challenges. Driven by the conviction that early adoption of new health technologies results in healthier and more productive societies, and that focusing on patients leads to good business results, he works closely with his teams to find novel ways to bring MSD’s medicines and vaccines to those who need them.
Kåre Engkilde, Executive Leader, Smile Incubator
Kåre Engkilde is an executive leader in the life science industry, with more than a decade of experiences covering diagnostics, medtech and therapeutics. He has brought cell-therapy to the clinic and be engaged in licensing, co-developments, and commercial discussions. He has worked for both big corporates and smaller entities and is presently advising companies in the SmiLe Incubator.
Ashley Cox, Senior Principal, Head of Europe, EMC
Ashley is the Senior Principal, Head of Europe, with EVERSANA MANAGEMENT CONSULTING and has almost two decades of experience spanning both commercial roles within mid-size Pharma and over a decade in leadership positions with global strategic consultancies. Ashley has supported decision-making across the majority of the top 20 pharma and many biotech companies. She started her career as a Medical Representative and has held a variety of commercial and licensing roles across the pharmaceutical and generics sectors.
David Byram, Senior Principal, EMC
David brings over 30 years of pharmaceutical, biotechnology, device and diagnostic industry leadership experience in market access, reimbursement, HEOR government affairs, sales and marketing. David has an extensive background in life sciences management consulting focused on the disciplines of market access, launch planning, pricing, payer contracting, value dossier creation, channel and distribution, coding and reimbursement and public policy supporting rare disease, oncology, specialty, controlled substances and general medicine. David co-led the development of the reimbursement methodology for biologic medicines as part of the 2003 Medicare Modernization Act and supported the development of the essential health benefits as part of the 2010 Affordable Care Act.

Jim Lang, CEO, EVERSANA
As Chief Executive Officer, Jim leads EVERSANA’s vision to accelerate the industry’s shift to patient-centered, value-based care – creating a healthier world for all. Lang brings more than 30 years of senior leadership experience in leading, advising and funding mission-driven health care companies. Lang previously served as CEO for several large organizations, and also spent nearly two decades building a premier strategy consultant firm. He has been named to the PharmaVOICE 100 list in both 2020 and 2021 andd was awarded a PharmaVOICE Red Jacket in 2022. Lang holds a Master of Business Administration from Dartmouth University and is an executive advisor with Water Street Healthcare Partners.

Franjo Hanzl, Vice President Commercial Development Europe, EVERSANA
As a leader of the commercial team in Europe, Franjo helps clients solve complex industry challenges while supporting streamlined commercialization strategies that get innovative therapies to patients across borders. Franjo has extensive expertise in marketing, business development, and pharmaceutical partnership and alliance management through his work with branded and generic pharma in Europe, which also provides him with a deep knowledge of the pricing landscape.

 

Organized by In collaboration with